ID   PPP5_RAT                Reviewed;         499 AA.
AC   P53042;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   24-JUL-2024, entry version 183.
DE   RecName: Full=Serine/threonine-protein phosphatase 5;
DE            Short=PP5;
DE            EC=3.1.3.16 {ECO:0000269|PubMed:11523989, ECO:0000269|PubMed:11969423};
DE   AltName: Full=Protein phosphatase T;
DE            Short=PPT;
GN   Name=Ppp5c;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Testis;
RX   PubMed=8077208; DOI=10.1016/s0021-9258(17)31686-1;
RA   Becker W., Kentrup H., Klumpp S., Schultz J.E., Joost H.G.;
RT   "Molecular cloning of a protein serine/threonine phosphatase containing a
RT   putative regulatory tetratricopeptide repeat domain.";
RL   J. Biol. Chem. 269:22586-22592(1994).
RN   [2]
RP   FUNCTION AS PHOSPHATASE, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND
RP   MUTAGENESIS OF GLU-29; LYS-32; GLU-56; ILE-63; ARG-74; GLU-76; CYS-77;
RP   TYR-80; LYS-97 AND ARG-101.
RX   PubMed=11523989; DOI=10.1021/bi010999i;
RA   Kang H., Sayner S.L., Gross K.L., Russell L.C., Chinkers M.;
RT   "Identification of amino acids in the tetratricopeptide repeat and C-
RT   terminal domains of protein phosphatase 5 involved in autoinhibition and
RT   lipid activation.";
RL   Biochemistry 40:10485-10490(2001).
RN   [3]
RP   COFACTOR, ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=11969423; DOI=10.1021/bi016090h;
RA   Ramsey A.J., Chinkers M.;
RT   "Identification of potential physiological activators of protein
RT   phosphatase 5.";
RL   Biochemistry 41:5625-5632(2002).
RN   [4]
RP   FUNCTION AS PHOSPHATASE, INTERACTION WITH GNA12 AND GNA13, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=12176367; DOI=10.1016/s0960-9822(02)01034-5;
RA   Yamaguchi Y., Katoh H., Mori K., Negishi M.;
RT   "Galpha(12) and Galpha(13) interact with Ser/Thr protein phosphatase type 5
RT   and stimulate its phosphatase activity.";
RL   Curr. Biol. 12:1353-1358(2002).
RN   [5]
RP   FUNCTION IN DEPHOSPHORYLATING MAPT, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=15546861; DOI=10.1074/jbc.m410775200;
RA   Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X.;
RT   "Dephosphorylation of tau by protein phosphatase 5: impairment in
RT   Alzheimer's disease.";
RL   J. Biol. Chem. 280:1790-1796(2005).
RN   [6]
RP   FUNCTION IN MAPK SIGNALING.
RX   PubMed=16892053; DOI=10.1038/ncb1465;
RA   von Kriegsheim A., Pitt A., Grindlay G.J., Kolch W., Dhillon A.S.;
RT   "Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5.";
RL   Nat. Cell Biol. 8:1011-1016(2006).
RN   [7]
RP   FUNCTION IN RAC1 SIGNALING, ACTIVITY REGULATION, INTERACTION WITH RAC1, AND
RP   MUTAGENESIS OF LYS-93; LYS-126 AND TYR-451.
RX   PubMed=16549782; DOI=10.1073/pnas.0600080103;
RA   Gentile S., Darden T., Erxleben C., Romeo C., Russo A., Martin N.,
RA   Rossie S., Armstrong D.L.;
RT   "Rac GTPase signaling through the PP5 protein phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5202-5206(2006).
RN   [8]
RP   INTERACTION WITH CRY1 AND CRY2.
RX   PubMed=16790549; DOI=10.1073/pnas.0604138103;
RA   Partch C.L., Shields K.F., Thompson C.L., Selby C.P., Sancar A.;
RT   "Posttranslational regulation of the mammalian circadian clock by
RT   cryptochrome and protein phosphatase 5.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10467-10472(2006).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 16-499 IN COMPLEX WITH MAGNESIUM,
RP   COFACTOR, AND INTERACTION WITH HSP90AA1.
RX   PubMed=26182372; DOI=10.1042/bsr20150042;
RA   Haslbeck V., Drazic A., Eckl J.M., Alte F., Helmuth M., Popowicz G.,
RA   Schmidt W., Braun F., Weiwad M., Fischer G., Gemmecker G., Sattler M.,
RA   Striggow F., Groll M., Richter K.;
RT   "Selective activators of protein phosphatase 5 target the autoinhibitory
RT   mechanism.";
RL   Biosci. Rep. 35:E00210-E00210(2015).
CC   -!- FUNCTION: Serine/threonine-protein phosphatase that dephosphorylates a
CC       myriad of proteins involved in different signaling pathways including
CC       the kinases CSNK1E, ASK1/MAP3K5, PRKDC and RAF1, the nuclear receptors
CC       NR3C1, PPARG, ESR1 and ESR2, SMAD proteins and TAU/MAPT
CC       (PubMed:11523989, PubMed:12176367, PubMed:15546861, PubMed:16549782,
CC       PubMed:16892053). Implicated in wide ranging cellular processes,
CC       including apoptosis, differentiation, DNA damage response, cell
CC       survival, regulation of ion channels or circadian rhythms, in response
CC       to steroid and thyroid hormones, calcium, fatty acids, TGF-beta as well
CC       as oxidative and genotoxic stresses (By similarity). Participates in
CC       the control of DNA damage response mechanisms such as checkpoint
CC       activation and DNA damage repair through, for instance, the regulation
CC       ATM/ATR-signaling and dephosphorylation of PRKDC and TP53BP1 (By
CC       similarity). Inhibits ASK1/MAP3K5-mediated apoptosis induced by
CC       oxidative stress (By similarity). Plays a positive role in
CC       adipogenesis, mainly through the dephosphorylation and activation of
CC       PPARG transactivation function. Also dephosphorylates and inhibits the
CC       anti-adipogenic effect of NR3C1 (By similarity). Regulates the
CC       circadian rhythms, through the dephosphorylation and activation of
CC       CSNK1E (By similarity). May modulate TGF-beta signaling pathway by the
CC       regulation of SMAD3 phosphorylation and protein expression levels (By
CC       similarity). Dephosphorylates and may play a role in the regulation of
CC       TAU/MAPT (PubMed:15546861). Through their dephosphorylation, may play a
CC       role in the regulation of ions channels such as KCNH2
CC       (PubMed:16549782). Dephosphorylate FNIP1, disrupting interaction with
CC       HSP90AA1/Hsp90 (By similarity). {ECO:0000250|UniProtKB:P53041,
CC       ECO:0000250|UniProtKB:Q60676, ECO:0000269|PubMed:11523989,
CC       ECO:0000269|PubMed:12176367, ECO:0000269|PubMed:15546861,
CC       ECO:0000269|PubMed:16549782, ECO:0000269|PubMed:16892053}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-seryl-[protein] = L-seryl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83421; EC=3.1.3.16;
CC         Evidence={ECO:0000269|PubMed:11523989, ECO:0000269|PubMed:11969423};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630;
CC         Evidence={ECO:0000269|PubMed:11523989, ECO:0000269|PubMed:11969423};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-threonyl-[protein] = L-threonyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:61977; EC=3.1.3.16;
CC         Evidence={ECO:0000269|PubMed:11523989, ECO:0000269|PubMed:11969423};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005;
CC         Evidence={ECO:0000269|PubMed:11523989, ECO:0000269|PubMed:11969423};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11969423, ECO:0000269|PubMed:26182372};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:11969423, ECO:0000269|PubMed:26182372};
CC       Note=Binds 2 magnesium or manganese ions per subunit.
CC       {ECO:0000269|PubMed:11969423, ECO:0000269|PubMed:26182372};
CC   -!- ACTIVITY REGULATION: Autoinhibited. In the autoinhibited state, the TPR
CC       domain interacts with the catalytic region and prevents substrate
CC       access to the catalytic pocket. Allosterically activated by various
CC       polyunsaturated fatty acids, free long-chain fatty-acids and long-chain
CC       fatty acyl-CoA esters, arachidonic acid being the most effective
CC       activator. HSP90A and probably RAC1, GNA12 and GNA13 can also release
CC       the autoinhibition by the TPR repeat. Activation by RAC1, GNA12 and
CC       GNA13 is synergistic with the one produced by fatty acids binding.
CC       Inhibited by okadaic acid. {ECO:0000269|PubMed:11523989,
CC       ECO:0000269|PubMed:11969423, ECO:0000269|PubMed:16549782}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=12.1 uM for MAPT/TAU (at pH 7.4 and 30 degrees Celsius)
CC         {ECO:0000269|PubMed:15546861};
CC   -!- SUBUNIT: Probably forms a complex composed of chaperones HSP90 and
CC       HSP70, co-chaperones STIP1/HOP, CDC37, PPP5C, PTGES3/p23, TSC1 and
CC       client protein TSC2 (By similarity). Probably forms a complex composed
CC       of chaperones HSP90 and HSP70, co-chaperones CDC37, PPP5C, TSC1 and
CC       client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this complex does not
CC       contain co-chaperones STIP1/HOP and PTGES3/p23 (By similarity). Part of
CC       a complex with HSP90/HSP90AA1 and steroid receptors (By similarity).
CC       Interacts (via TPR repeats) with HSP90AA1 (via TPR repeat-binding
CC       motif) or HSPA1A/HSPA1B; the interaction is direct and activates the
CC       phosphatase activity (PubMed:26182372). Dissociates from HSPA1A/HSPA1B
CC       and HSP90AA1 in response to arachidonic acid (By similarity). Interacts
CC       with CPNE1 (via VWFA domain) (By similarity). Interacts with CDC16,
CC       CDC27 (By similarity). Interacts with KLHDC10 (via the 6 Kelch
CC       repeats); inhibits the phosphatase activity on MAP3K5 (By similarity).
CC       Interacts with ATM and ATR; both interactions are induced by DNA damage
CC       and enhance ATM and ATR kinase activity (By similarity). Interacts with
CC       RAD17; reduced by DNA damage (By similarity). Interacts with nuclear
CC       receptors such as NR3C1/GCR and PPARG (activated by agonist); regulates
CC       their transactivation activities (By similarity). Interacts (via TPR
CC       repeats) with S100 proteins S100A1, S100A2, S100A6, S100B and S100P;
CC       the interactions are calcium-dependent, strongly activate PPP5C
CC       phosphatase activity and compete with HSP90AA1 and MAP3K5 interactions
CC       (By similarity). Interacts with SMAD2 and SMAD3 but not with SMAD1;
CC       decreases SMAD3 phosphorylation and protein levels (By similarity).
CC       Interacts (via TPR repeats) with CRY1 and CRY2; the interaction with
CC       CRY2 down-regulates the phosphatase activity on CSNK1E
CC       (PubMed:16790549). Interacts (via TPR repeats) with the active form of
CC       RAC1, GNA12 or GNA13; these interactions activate the phosphatase
CC       activity and translocate PPP5C to the cell membrane (PubMed:12176367,
CC       PubMed:16549782). Interacts with FLCN (By similarity).
CC       {ECO:0000250|UniProtKB:P53041, ECO:0000250|UniProtKB:Q60676,
CC       ECO:0000269|PubMed:12176367, ECO:0000269|PubMed:16549782,
CC       ECO:0000269|PubMed:16790549, ECO:0000269|PubMed:26182372}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12176367}. Cytoplasm
CC       {ECO:0000269|PubMed:12176367}. Cell membrane
CC       {ECO:0000250|UniProtKB:P53041}. Note=Predominantly nuclear. But also
CC       present in the cytoplasm. Translocates from the cytoplasm to the plasma
CC       membrane in a RAC1-dependent manner. {ECO:0000250|UniProtKB:P53041}.
CC   -!- TISSUE SPECIFICITY: Predominantly found in brain and, in lower levels,
CC       in testis, but was nearly undetectable in spleen, lung, skeletal
CC       muscle, kidney and liver. {ECO:0000269|PubMed:15546861}.
CC   -!- PTM: Activated by at least two different proteolytic cleavages
CC       producing a 56 kDa and a 50 kDa form. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the PPP phosphatase family. PP-5 (PP-T)
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X77237; CAA54454.1; -; mRNA.
DR   PIR; A55346; A55346.
DR   RefSeq; NP_113917.1; NM_031729.1.
DR   PDB; 4JA7; X-ray; 2.00 A; A=16-499.
DR   PDB; 4JA9; X-ray; 2.30 A; A=16-499.
DR   PDBsum; 4JA7; -.
DR   PDBsum; 4JA9; -.
DR   AlphaFoldDB; P53042; -.
DR   SMR; P53042; -.
DR   BioGRID; 249291; 3.
DR   DIP; DIP-61212N; -.
DR   IntAct; P53042; 2.
DR   STRING; 10116.ENSRNOP00000023078; -.
DR   iPTMnet; P53042; -.
DR   PhosphoSitePlus; P53042; -.
DR   SwissPalm; P53042; -.
DR   jPOST; P53042; -.
DR   PaxDb; 10116-ENSRNOP00000023078; -.
DR   Ensembl; ENSRNOT00000023078.6; ENSRNOP00000023078.3; ENSRNOG00000016907.6.
DR   Ensembl; ENSRNOT00055055135; ENSRNOP00055045579; ENSRNOG00055031841.
DR   Ensembl; ENSRNOT00060039433; ENSRNOP00060032621; ENSRNOG00060022634.
DR   Ensembl; ENSRNOT00065056658; ENSRNOP00065046637; ENSRNOG00065032929.
DR   GeneID; 65179; -.
DR   KEGG; rno:65179; -.
DR   UCSC; RGD:68415; rat.
DR   AGR; RGD:68415; -.
DR   CTD; 5536; -.
DR   RGD; 68415; Ppp5c.
DR   eggNOG; KOG0376; Eukaryota.
DR   GeneTree; ENSGT00940000158785; -.
DR   HOGENOM; CLU_004962_5_2_1; -.
DR   InParanoid; P53042; -.
DR   OrthoDB; 1107740at2759; -.
DR   PhylomeDB; P53042; -.
DR   TreeFam; TF105562; -.
DR   BRENDA; 3.1.3.16; 5301.
DR   Reactome; R-RNO-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-RNO-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-RNO-8939211; ESR-mediated signaling.
DR   SABIO-RK; P53042; -.
DR   EvolutionaryTrace; P53042; -.
DR   PRO; PR:P53042; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000016907; Expressed in cerebellum and 20 other cell types or tissues.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0043204; C:perikaryon; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0101031; C:protein folding chaperone complex; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:1990635; C:proximal dendrite; IDA:RGD.
DR   GO; GO:0043531; F:ADP binding; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; ISO:RGD.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IDA:RGD.
DR   GO; GO:0031072; F:heat shock protein binding; IPI:RGD.
DR   GO; GO:0051879; F:Hsp90 protein binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008017; F:microtubule binding; IDA:RGD.
DR   GO; GO:0017018; F:myosin phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016791; F:phosphatase activity; ISO:RGD.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:ARUK-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0003723; F:RNA binding; ISO:RGD.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IEP:RGD.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEP:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IMP:RGD.
DR   GO; GO:0070262; P:peptidyl-serine dephosphorylation; ISS:UniProtKB.
DR   GO; GO:2000324; P:positive regulation of glucocorticoid receptor signaling pathway; IMP:RGD.
DR   GO; GO:1904550; P:response to arachidonic acid; IDA:ARUK-UCL.
DR   GO; GO:0010288; P:response to lead ion; IDA:ARUK-UCL.
DR   GO; GO:0043278; P:response to morphine; ISO:RGD.
DR   CDD; cd07417; MPP_PP5_C; 1.
DR   Gene3D; 3.60.21.10; -; 1.
DR   Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1.
DR   InterPro; IPR004843; Calcineurin-like_PHP_ApaH.
DR   InterPro; IPR029052; Metallo-depent_PP-like.
DR   InterPro; IPR041753; PP5_C.
DR   InterPro; IPR013235; PPP_dom.
DR   InterPro; IPR051134; PPP_phosphatase.
DR   InterPro; IPR006186; Ser/Thr-sp_prot-phosphatase.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   PANTHER; PTHR45668; SERINE/THREONINE-PROTEIN PHOSPHATASE 5-RELATED; 1.
DR   PANTHER; PTHR45668:SF5; SERINE_THREONINE-PROTEIN PHOSPHATASE 5; 1.
DR   Pfam; PF00149; Metallophos; 1.
DR   Pfam; PF08321; PPP5; 1.
DR   Pfam; PF00515; TPR_1; 1.
DR   PIRSF; PIRSF033096; PPPtase_5; 1.
DR   PRINTS; PR00114; STPHPHTASE.
DR   SMART; SM00156; PP2Ac; 1.
DR   SMART; SM00028; TPR; 3.
DR   SUPFAM; SSF56300; Metallo-dependent phosphatases; 1.
DR   SUPFAM; SSF48452; TPR-like; 1.
DR   PROSITE; PS00125; SER_THR_PHOSPHATASE; 1.
DR   PROSITE; PS50005; TPR; 3.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell membrane; Cytoplasm; Hydrolase; Magnesium;
KW   Manganese; Membrane; Metal-binding; Nucleus; Protein phosphatase;
KW   Reference proteome; Repeat; TPR repeat.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P53041"
FT   CHAIN           2..499
FT                   /note="Serine/threonine-protein phosphatase 5"
FT                   /id="PRO_0000058897"
FT   REPEAT          28..61
FT                   /note="TPR 1"
FT   REPEAT          62..95
FT                   /note="TPR 2"
FT   REPEAT          96..129
FT                   /note="TPR 3"
FT   REGION          1..23
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          200..499
FT                   /note="Catalytic"
FT   REGION          495..499
FT                   /note="Required for autoinhibition"
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   COMPBIAS        9..23
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        304
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P53041"
FT   BINDING         242
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:26182372,
FT                   ECO:0007744|PDB:4JA7"
FT   BINDING         244
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:26182372,
FT                   ECO:0007744|PDB:4JA7"
FT   BINDING         244
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P53041"
FT   BINDING         271
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:26182372,
FT                   ECO:0007744|PDB:4JA7"
FT   BINDING         271
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:26182372,
FT                   ECO:0007744|PDB:4JA7, ECO:0007744|PDB:4JA9"
FT   BINDING         275
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P53041"
FT   BINDING         303..304
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P53041"
FT   BINDING         303
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:26182372,
FT                   ECO:0007744|PDB:4JA7, ECO:0007744|PDB:4JA9"
FT   BINDING         352
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:26182372,
FT                   ECO:0007744|PDB:4JA7, ECO:0007744|PDB:4JA9"
FT   BINDING         400
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P53041"
FT   BINDING         427
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:26182372,
FT                   ECO:0007744|PDB:4JA7, ECO:0007744|PDB:4JA9"
FT   BINDING         427
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P53041"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:P53041"
FT   MUTAGEN         29
FT                   /note="E->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         32
FT                   /note="K->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         40
FT                   /note="K->A: Slightly reduces activation by arachidonic
FT                   acid."
FT   MUTAGEN         56
FT                   /note="E->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         63
FT                   /note="I->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         74
FT                   /note="R->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         76
FT                   /note="E->A: Increases basal phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         77
FT                   /note="C->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         80
FT                   /note="Y->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         93
FT                   /note="K->E: Loss of inhibition of KCNH2 channel
FT                   stimulation."
FT                   /evidence="ECO:0000269|PubMed:16549782"
FT   MUTAGEN         97
FT                   /note="K->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         101
FT                   /note="R->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:11523989"
FT   MUTAGEN         126
FT                   /note="K->A: Loss of inhibition of KCNH2 channel
FT                   stimulation."
FT                   /evidence="ECO:0000269|PubMed:16549782"
FT   MUTAGEN         451
FT                   /note="Y->A: Insensitive to okadaic acid."
FT                   /evidence="ECO:0000269|PubMed:16549782"
FT   HELIX           24..40
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           44..57
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           62..74
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           78..91
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           96..108
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           112..125
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           130..148
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           161..164
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           167..169
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           188..199
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           206..221
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          225..229
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          236..240
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           247..257
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          262..264
FT                   /evidence="ECO:0007829|PDB:4JA9"
FT   STRAND          266..270
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          273..276
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           279..292
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   TURN            294..296
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          297..300
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           307..313
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           315..322
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           325..335
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          340..344
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   TURN            345..347
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          348..353
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          357..359
FT                   /evidence="ECO:0007829|PDB:4JA9"
FT   HELIX           363..367
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          372..374
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          377..379
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           380..386
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          391..397
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          401..406
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           408..418
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          422..425
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          433..437
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           438..440
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          442..445
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           451..453
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          459..465
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   STRAND          468..476
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   TURN            486..489
FT                   /evidence="ECO:0007829|PDB:4JA7"
FT   HELIX           492..494
FT                   /evidence="ECO:0007829|PDB:4JA9"
SQ   SEQUENCE   499 AA;  56917 MW;  720A7FB7AFC701D2 CRC64;
     MAMAEGERTE CAEPPRDEPP AEGTLKRAEE LKTQANDYFK AKDYENAIKF YSQAIELNPS
     NAIYYGNRSL AYLRTECYGY ALGDATRAIE LDKKYIKGYY RRAASNMALG KFRAALRDYE
     TVVKVKPNDK DAKMKYQECS KIVKQKAFER AIAGDEHRRS VVDSLDIESM TIEDEYSGPK
     LEDGKVTITF MKDLMQWYKD QKKLHRKCAY QILVQVKEVL CKLSTLVETT LKETEKITVC
     GDTHGQFYDL LNIFELNGLP SETNPYIFNG DFVDRGSFSV EVILTLFGFK LLYPDHFHLL
     RGNHETDNMN QIYGFEGEVK AKYTAQMYEL FSEVFEWLPL AQCINGKVLI MHGGLFSEDG
     VTLDDIRKIE RNRQPPDSGP MCDLLWSDPQ PQNGRSVSKR GVSCQFGPDV TKAFLEENQL
     DYIIRSHEVK AEGYEVAHGG RCVTVFSAPN YCDQMGNKAS YIHLQGSDLR PQFHQFTAVP
     HPNVKPMAYA NTLLQLGMM
//
